Mr. Scavilla said, “I am honored to join the Board and continue to drive forward Dentsply Sirona’s mission of transforming and advancing innovation. As a longtime executive in the healthcare industry, ...

Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal ... broader and more diversified leader in the pain management space." The $5.85 per share consideration ...

with significant benefits expected for chronic pain management solutions. Globus Medical reported preliminary sales projections for 2024 of $2.52 billion, while Nevro expects revenues between $408 ...

Debt Management: Globus Medical's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.